Fraunhofer ITEM: News

News / 12.1.2024

Reinforcing core competencies

Succession to Professor Thomas Thum to act as institute director of Fraunhofer ITEM and take up new role as chair of Toxicology at MHH.

News / 21.11.2023

Rapid therapies against viral diseases

As a finalist in the third round of the SPRIND Challenge, iGUARD receives follow-up funding of 2.5 million euros. 

 

Project / 19.9.2023

Environmental risk assessment (ERA)

Why does the environmental risk assessment for drugs need to be updated? 

3.4.2023

Smart Health: Projekt "PrivacyUmbrella"

Ensure privacy of data through comprehensive deployment anonymization procedures.

News / 12.6.2023

Environmental assessment of chemicals

Final report published: Review of the OECD Test Guidelines.

 

News / 26.1.2024

Research on alternatives to animal studies on behalf of European Chemicals Agency (ECHA)

Scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal studies.

 

Highlight / 18.9.2023

Toxicological risk assessment for PFAS

What amount of PFAS is it safe to ingest? At Fraunhofer ITEM, we are investigating how PFAS impact people’s health. 

Project / 29.6.2023

Project Genealyzer

Web application for the analysis and comparison of gene expression data.

Our research and development expertise

For more than four decades, we have been developing solutions for human health

 

Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.

 

Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.

 

RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

 

Toxicology

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

 

Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services

 

Chemical Safety and Assessment

 

Translational Biomedical Engineering

 

Personalized Tumor Therapy

From molecular analysis to personalized therapy:

 

Meet Fraunhofer ITEM at fairs and congresses

Events

20.6.2024

Models of Lung Disease 2024

Please save the date for the 22nd Fraunhofer Seminar "Models of Lung Disease". We would be pleased to welcoming you there.
more info

11.6.2024

Workshop "Alternatives to Animal Testing 2024"

3R-research in the focus: The workshop »Alternatives to Animal Testing« will be taking place at Fraunhofer ITEM in Hannover on June 11, 2024.
more info

7.4.2024

AACR Annual Meeting 2024

Fraunhofer IIS’s Medical Image Analysis group and Fraunhofer ITEM’s Personalized Tumor Therapy division attend the next annual meeting of the American Association of Cancer Research in 2024 and exhibit their technologies and services.
more info

21.3.2024

ATC Conference 2024

The 31st ATC Conference will be held from March 21 - 22, 2024, for the first time under Fraunhofer umbrella at the Fraunhofer Institute for Silicate Research ISC in Würzburg, a member of the Fraunhofer Chemistry Alliance, like the Fraunhofer ITEM. Dr. Annette Bitsch (Fraunhofer ITEM) will be held a tandem talk with Dr. Bernd Göckener (Fraunhofer IME) about the toxicology of PFAS.
more info

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on lung research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

 

More information about Fraunhofer ITEM